Roche's Avastin wins EU approval for additional indication UPDATE |
|
|
|
Published
:
Fri, 24 Aug 2007 07:19
|
(Updating with additional information)ZURICH (Thomson Financial) - Roche Holding AG said its cancer treatment Avastin has been approved in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.NSCLC is the most common form of lung cancer, a difficult to treat disease, killing over 3,000 people per day worldwide.Avastin is the only first-line therapy to demonstrate improved survival benefits beyond one year in patients with advanced NSCLC, the Swiss pharma group said.Today's approval is based on data from the pivotal US phase III trial (E4599) and the 'Avastin in Lung' (AVAiL) phase III trial.andrew.ge.thompson@thomson.comat/jlw/at/jlw/jmt/rwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2251.69 |
-12.87 (
-0.56 %)
|
| SYMBOL (
2010-07-29 ) |
| LAST |
CHANGE
|
|
KAZAKHMYS
(
11:37am )
|
|
1220.00 |
+23.00 (
1.91 %)
|
|
LONMIN
(
11:35am )
|
|
1580.00 |
+21.00 (
1.35 %)
|
|
SHIRE
(
11:35am )
|
|
1490.00 |
+21.00 (
1.43 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
DUPONT
(
4:00pm ) |
|
40.51 |
+0.24 (
0.59 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Roche's Avastin receives positive EU opinion as lung cancer treatment 